Thank you. And hi everyone, and welcome to Cinclus Pharma's second quarter 2026 earnings call. I am Christer Ahlberg and I'm CEO of Cinclus Pharma. And with me here today, I also have our CFO, Magnus Christensen. And we will walk you through the key developments from the second quarter, after which we will be happy to answer any questions you may have. Our lead asset, linaprazan glurate, is the next-generation PCAB, and that substance offers sustained around-the-clock acid control that distinguishes it from the current standard of care with proton pump inhibitors, the PPIs, and all other PCABs available on the market or in development, specifically for severe erosive GERD. The patient population we are addressing is large and underserved. Roughly 10 million people across the US and Europe live with severe erosive GERD, and a substantial share of them are not adequately healed or treated by today's standard of care. This makes this a specialty-driven commercial opportunity rather than a primary care one. Better healing and better symptom control translate directly into clinical and commercial differentiation. And that's our goal.
Our Phase III program, HEEALING1, began in September 2025, and I am very pleased to report that it has completed enrollment; in early July, we announced that we had exceeded the protocol-specified target number of patients. That was very good news for us. HEEALING1 topline results are expected in the fourth quarter of this year, as previously communicated, which could represent a major value inflection point for the company. Our program is de-risked at this stage. We have a robust clinical data package, alignment with both the US FDA and the European EMA regarding our regulatory strategy, and we have a well-defined CMC plan that we have already communicated before. Linaprazan glurate has, in 2026, been launched in China as planned through our Sinorda licensing agreement and also through their partner Huadong, which is the second-biggest pharma company in China. We are also restricted from giving any details about the launch at this stage. But of course it looks very promising, and we are progressing very well during the launch in China. And we are, of course, excited that we have seen the first commercial launch of linaprazan glurate globally. And it is, of course, a very important validation of the drug. We see that the first-generation PCABs are rapidly gaining traction. PCABs are now available in more than 30 countries globally, and local treatment guidelines are increasingly adopting recommendations. And that is, of course, very good for us. There is no doubt that PCABs are about to take over the market from the current standard treatment with proton pump inhibitors like Losec and Nexium and other products in that group. Regarding the enrollment completion of the Phase III study, we are very pleased with the execution of the first Phase III study, HEEALING1, which has developed according to our plans since the start last fall. We announced in early July that our enrollment in the study was completed, and at that time, we had randomized 521 patients, exceeding our protocol-specified target of 501 patients. The total number of patients in the study now is actually 523, and the study is being conducted across eight European countries. The primary endpoint is superiority to lansoprazole. That is a unique primary endpoint. And we are going to deliver it in the healing of severe erosive GERD patients, specifically LA grade C and D, and we are going to deliver on that. After four weeks of treatment. Key secondary endpoints cover healing. Of course, it covers symptom relief through four weeks, but also through eight weeks. For both LA grade C and D patients. But also, of course, all patients. So all grades as well. A, B, C and D. And the study will be followed by our second and final Phase III study, HEEALING2. That will also evaluate maintenance therapy and will be done at clinical sites in both Europe and the US as well. HEEALING2 is planned to initiate following HEEALING1 topline results. This slide highlights our HEEALING1 progress. We screened the last patient in June and reached our enrollment target, having randomized the last patients in July. The remaining milestones are outlined below. The topline results for the last patient treated are expected within a few weeks, and the last patient's last visit is expected in September or October this fall, which will conclude the clinical phase. Thereafter, the remaining steps will be data cleaning and database lock. And finally, the readout that we expect during the fourth quarter of the year. We have good visibility over the remaining timeline of the study. This slide you have seen before, but it is very important. It shows how well a drug controls gastric acid over a 24-hour day. It predicts how well it heals the erosive GERD patients. The relationship is linear, as you can see. Whether you look at PPIs or PCABs? That is the central scientific argument for the linear dose-response at this stage, as acid control is the biomarker that drives healing in this disease, and the more of the day, the 24 hours you can keep gastric pH above four, the better. The better it is for the patients. And that is precisely the variable under which linaprazan glurate is differentiated. But that has also been our aim and objective since we began developing the product. This slide illustrates the number of hours the pH in the stomach is below pH 4 for different treatments. Given the treatment alternatives available in the market. Over the. Over the study period. Over the decades and the history of the development of these kinds of drugs with the old H2 blockers, you can see to the left, such as Zantac, that were launched during the. In the 70s, pH was below four during 16 hours per day, but still, it was a dramatic improvement compared to having nothing. And this drug became the most sold drug in the world and actually built Glaxo into the big pharma company it is today, looking into the development of the next step for the proton pump inhibitor that came to the market in the end of the 80s and the beginning of the 90s. Here you can see a reduction between 7 to 14 hours with PPIs. Below pH four and that, as you know, these drugs Losec, Prilosec, and Nexium became the most sold drugs in the world at the same time, and that actually built Astra and AstraZeneca into what they are today. So these drugs are important for companies. And when they are developing the company, and also when we see now the next step in this evolution, you see that the first generation of PCABs were launched in 2015 and now in 2024 in the US, where you can see that you have another dramatic step downwards in hours of pH below four. Actually, what they managed to do in Japan, where it was launched first, was to become the most sold drug in Japan. And with close to 1 billion USD in sales only there. So, of course, acid control improvement matters to actually build the market and to build companies launching these kinds of products. And what you can see now is that our studies show that linaprazan glurate has a unique ability to maintain pH below four for only one hour per day. This is a major improvement to all existing treatment alternatives on the market and in development, highlighting a significant market potential as you understand. This is really the end of the treatment ladder. You can say that now you have reached the goal that also can help the severely ill patients. And also, if you remember the slide I showed you before with the biomarker relating the linear correlation between acid control and the healing of these patients. We also wanted to control this and double-check if it works also for PCAB. And the last study that has been performed, the Phase III trials being performed in the US and Europe with Vonoprazan. Tegoprazan. They have used the same comparator of the PPI, Lansoprazole. And if we start from the beginning here with the acid control of each of these drugs. Lansoprazole is actually interesting to see when you plot these results into the curve that we showed you before. The biomarker curve is spot on. It is perfectly spot on. Related also to this curve. So if you actually look at the acid control, Lansoprazole is 63% after eight weeks. And in the results of the clinical studies of the Phase III clinical studies of Tegoprazan and Vonoprazan in the US and Europe, they came to a conclusion of 68% to 72%. That is perfectly on the line. Which is perfectly on the biomarker line I showed you before going further into Tegoprazan, which has an acid control of 75%. And actually, their clinical data showed 83% healing in the Phase III trial after eight weeks for LA grade C/D patients. And if you just compare 75% into this curve, you see it is perfectly on the line of 80% plus in healing. Looking into vonoprazan, they have a slightly higher control rate of up to 85%. And if you look at their clinical data from the phase three, they reached 91.7% healing of the C and D patients after eight weeks. It is also perfectly spot on the curve. So you can really predict outcomes with this data and this curve. And therefore it is very interesting to see that we have 96%.
It will be very interesting to follow our healing rates after eight weeks for the LA grade C and D patients coming to the end of the year, when we know the results from our Phase III study. But of course, our ambition is to have in absolute figures also the best healing rates for the C and D patients, but not only the best healing rates. We also look forward to demonstrating the benefits of our unique acid control. We also want to have the biggest effect difference compared to the PPIs. The biggest delta. As we call it, in our phase two trial, we delivered a 55% delta in absolute percentage figures, 93% versus 38% for the PPIs, which is 55 percentage points in difference. If you look into the other PCABs, they have delivered something between 15% to 20% delta compared to the same comparator, lansoprazole, after two and eight weeks. And of course, we want to have the best healing rates, but we also want to deliver the best delta, the effect difference between ourselves and the PPI that we are comparing with. That is the same as what Vonoprazan and Tegoprazan have done. So we will have a uniqueness in reaching the best-in-class positioning here. On top of that, we also want to deliver superiority in symptom relief versus the PPI, both in daytime and nighttime symptoms. And if we can do that, which we have good chances to do, this could definitely be a game changer and a unique position. Best-in-class position that no one has delivered before. And that is, of course, something that we have aimed for. And that is of course done thanks to the uniqueness of our acid control. That was the aim from the beginning when we developed this product, that we should have total acid control, which could also have a chance to help the most severe patients.
Okay, I think I will stop there, and then we can move into some financials.
And I hand over then to you, Magnus.